See the DrugPatentWatch profile for Mounjaro
Mounjaro, a medication for type 2 diabetes and chronic weight management, is available in a carton containing four 2.5 mg/0.5 mL pens [1]. The National Drug Code (NDC) for this specific presentation is not provided in the given information.
What is Mounjaro used for?
Mounjaro (tirzepatide) is indicated for the treatment of type 2 diabetes in adults, in addition to diet and exercise. It is also approved for chronic weight management in adults with obesity or who are overweight with at least one weight-related comorbidity [1].
What are the different Mounjaro dosages?
Mounjaro is available in multiple dosages, including 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg, with each dose delivered in a 0.5 mL injection [1].
How does Mounjaro work?
Tirzepatide, the active ingredient in Mounjaro, is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. By activating these receptors, it helps to lower blood glucose levels and promote weight loss [1].
What is the pricing and insurance coverage for Mounjaro?
Pricing and insurance coverage for Mounjaro can vary significantly. Patients may find savings programs available through the manufacturer [1].
When does Mounjaro's patent expire?
Information regarding Mounjaro's patent expiration is available through specialized resources [2].
Who manufactures Mounjaro?
Mounjaro is manufactured by Eli Lilly and Company [1].
What are the potential side effects of Mounjaro?
Common side effects of Mounjaro include nausea, vomiting, diarrhea, constipation, abdominal pain, and decreased appetite. Serious side effects can occur, such as pancreatitis, gallbladder problems, kidney problems, severe allergic reactions, and thyroid tumors. Patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 should not use Mounjaro [1].
Are there alternative treatments for type 2 diabetes and weight management?
Yes, other medications and lifestyle interventions are available for type 2 diabetes and weight management. These may include other GLP-1 receptor agonists, insulin, metformin, and various weight loss programs [3].
---
Sources:
[1] Mounjaro.com
[2] DrugPatentWatch.com
[3] National Institute of Diabetes and Digestive and Kidney Diseases